Abdellah Yamani

发表

Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).

A. Yamani, K. Dzwonek, M. Wieczorek, 2020, European journal of medicinal chemistry.

Identification of small-molecule enhancers of arginine methylation catalyzed by coactivator-associated arginine methyltransferase 1.

E. Novellino, A. Mai, G. Sbardella, 2012, Journal of medicinal chemistry.

Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents.

A. Yamani, A. Haemers, K. Augustyns, 2001, Current pharmaceutical design.

Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at P1' and P4 positions.

Y. Kiso, Y. Hamada, Tooru Kimura, 2010, Bioorganic & medicinal chemistry.

Views on amyloid hypothesis and secretase inhibitors for treating Alzheimer's disease: progress and problems.

Y. Kiso, J. Nguyen, A. Yamani, 2006, Current pharmaceutical design.

Significance of interactions of BACE1-Arg235 with its ligands and design of BACE1 inhibitors with P2 pyridine scaffold.

Y. Kiso, Y. Hamada, S. Ishiura, 2009, Bioorganic & medicinal chemistry letters.

Novel non-peptidic and small-sized BACE1 inhibitors.

Kazuki Saito, Y. Kiso, Y. Hamada, 2008, Bioorganic & medicinal chemistry letters.

BACE1 inhibitors: optimization by replacing the P1' residue with non-acidic moiety.

Kazuki Saito, Y. Kiso, Y. Hamada, 2008, Bioorganic & medicinal chemistry letters.

beta-Secretase inhibitors: modification at the P4 position and improvement of inhibitory activity in cultured cells.

Kazuki Saito, Y. Kiso, Y. Hamada, 2006, Bioorganic & medicinal chemistry letters.